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CD4 T cells can respond to TCR signaling with 
full activation and the acquisition of effector 
functions or with anergy, a state of unresponsive-
ness characterized by the inability to proliferate 
and display effector functions, including cytokine 
secretion in response to secondary stimulation 
(Schwartz, 2003). Two-signal models of T cell 
activation state that to elicit full T cell activa-
tion, TCR engagement must be accompanied by 
co-stimulation (Schwartz, 2003). Full T cell activa-
tion and induction of Il2 transcription is promoted 
by co-ligation of TCR and CD28 (Thompson 
et al., 1989; Linsley et al., 1991; Harding et al., 
1992) through activation of phospholipase C 
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T cell receptor (TCR) signals can elicit full activation with acquisition of effector functions 
or a state of anergy. Here, we ask whether microRNAs affect the interpretation of TCR 
signaling. We find that Dicer-deficient CD4 T cells fail to correctly discriminate between 
activating and anergy-inducing stimuli and produce IL-2 in the absence of co-stimulation. 
Excess IL-2 production by Dicer-deficient CD4 T cells was sufficient to override anergy 
induction in WT T cells and to restore inducible Foxp3 expression in Il2-deficient CD4  
T cells. Phosphorylation of Akt on S473 and of S6 ribosomal protein was increased and 
sustained in Dicer-deficient CD4 T cells, indicating elevated mTOR activity. The mTOR 
components Mtor and Rictor were posttranscriptionally deregulated, and the microRNAs 
Let-7 and miR-16 targeted the Mtor and Rictor mRNAs. Remarkably, returning Mtor and 
Rictor to normal levels by deleting one allele of Mtor and one allele of Rictor was sufficient 
to reduce Akt S473 phosphorylation and to reduce co-stimulation–independent IL-2 pro-
duction in Dicer-deficient CD4 T cells. These results show that microRNAs regulate the 
expression of mTOR components in T cells, and that this regulation is critical for the modu-
lation of mTOR activity. Hence, microRNAs contribute to the discrimination between T cell 
activation and anergy.
© 2014 Marcais et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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Conversely, T cell activation is impaired when microRNA 
expression is increased by the deletion of the RNase Eri1 
(Thomas et al., 2012).
To gain insight into the role of posttranscriptional regulation 
of signaling components we have examined CD4 T cell acti-
vation in the absence of the RNseIII enzyme Dicer, which is 
a key component of the microRNA biogenesis pathway (Cobb 
et al., 2005, 2006; Muljo et al., 2005). We found that Dicer-
deficient CD4 T cells had an intrinsically low threshold for 
TCR signals and were competent to produce IL-2 in the ab-
sence of co-stimulatory signals. Co-stimulation–independent 
IL-2 production perpetuated T cell activation signals in an 
autocrine and paracrine fashion, abrogated the discrimination 
between activating and anergizing signals, and enabled T cell 
proliferation in response to TCR signals alone.
mRNA and protein expression profiling and analysis of 
TCR-induced signaling showed elevated phosphorylation of 
Akt S473 and S6 ribosomal protein, indicating hyperactivity 
of the mechanistic target of rapamycin (mTOR) complexes 
mTORC1 (which phosphorylates S6) and mTORC2 (which 
phosphorylates Akt on S473; Sarbassov et al., 2006) and over-
expression of the mTOR complex components Mtor and 
Rictor. Mtor and Rictor transcripts were up-regulated at the 
posttranscriptional level, and targeted by microRNAs, in-
cluding miR-16 and Let-7. Remarkably, we found that the 
key signaling abnormalities of microRNA-deficient CD4 
T cells, namely increased Akt S473 phosphorylation and co- 
stimulation–independent Il2 transcription were dependent 
on elevated Mtor and Rictor expression, and could be re-
versed by returning Mtor and Rictor to WT levels.
RESULTS
Dicer-deficient CD4 T cells show heightened  
sensitivity to TCR signaling, IL-2 production,  
and proliferation in the absence of co-stimulation
To deplete microRNAs from peripheral T cells, we reconsti-
tuted irradiated (CD45.1) hosts with allotypically marked 
CD45.2 ERt2Cre Dicerwt/wt or ERt2Cre Dicerlox/lox BM, and 
administered tamoxifen to fully reconstituted chimeras (Fig. 1 a). 
Naive CD25 CD62Lhi CD45.2+ CD4 T cells isolated from 
these mice showed near-complete loss of Dicer1 mRNA and 
a substantial reduction in the expression of Dicer-dependent 
microRNAs, including miR-16 and Let-7c (Fig. 1 b). Naive 
ERt2Cre Dicerwt/wt and ERt2Cre Dicer/ CD25 CD62Lhi 
CD4 T cells were activated with graded concentrations of 
plate-bound TCR antibody (H57) alone or in the presence of 
anti-CD28 as a source of co-stimulation. The percentage of cells 
expressing CD69 and CD25 was determined by flow cytom-
etry 24 h later. In the presence of co-stimulation, both control 
(black bars) and Dicer-deficient CD4 T cells (red bars) initi-
ated the expression of the activation markers CD69 (Fig. 1 c, 
left) and CD25 (Fig. 1 c, right). At limiting concentrations of 
TCR antibody, Dicer-deficient CD4 T cells were markedly 
more sensitive to TCR signals than control CD4 T cells, as 
indicated by a higher percentage of cells that expressed CD69 
(Fig. 1 c, left) and CD25 (Fig. 1 c, right).
(PLC)-1, Ras, and protein kinase C (PKC), activation of 
the MAPK, JNK, PI3K/Akt, and IB kinase (IKK) pathways, 
mobilization of intracellular calcium, and activation of the 
transcription factors NFAT, AP-1, CREB, and NF-B, result-
ing in Il2 transcription (Wells, 2009). TCR engagement in the 
absence of CD28 co-stimulation results in limited AP-1 and 
NF-B activity, defective transactivation of the Il2 promoter, and 
induction of anergy (Schwartz, 2003). The early secretion of 
IL-2 is a key event that discriminates productive activation from 
anergy (Thompson et al., 1989; Linsley et al., 1991; Harding 
et al., 1992). IL-2 is necessary (DeSilva et al., 1991) and suffi-
cient (Zheng et al., 2007) to avoid anergy in response to TCR 
engagement through signaling pathways that include PI3K and 
mTOR (Powell and Delgoffe, 2010; Liou and Smith, 2011), a 
PI3K-related Ser/Thr kinase that integrates signals from several 
pathways including TCR signaling and cellular metabolism 
(Wells, 2009; Powell and Delgoffe, 2010; Araki et al., 2011).
Anergy-inducing stimuli may act in part by inducing the 
degradation of signaling molecules (Heissmeyer et al., 2004), 
and evidence that the activation versus anergy decision is af-
fected by the abundance of signaling components comes from 
the involvement in this process of E3 ubiquitin ligases, enzymes 
that mediate the proteolytic turnover of signaling molecules: 
Cbl-b, Itch, and GRAIL are up-regulated in T cells under 
anergizing stimuli and required for anergy induction (Paolino 
and Penninger, 2010). Similarly, caspase 3 promotes anergy 
by degrading GADS (Grb2-related adaptor of downstream of 
Shc) and Vav (Puga et al., 2008). Hence, several negative regu-
lators contribute to activation versus anergy discrimination 
by accelerating the turnover of signaling molecules downstream 
of the TCR. In addition to their turnover, the abundance of 
signaling components is determined by the transcriptional and 
posttranscriptional regulation of their production. microRNAs 
regulate gene expression at the posttranscriptional level 
through mRNA stability and translation (Selbach et al., 2008). 
microRNAs control multiple aspects of T cell differentiation 
and activation, from initial signaling events (Li et al., 2007) to 
the acquisition of effector functions and cytokine production 
(Muljo et al., 2005; Steiner et al., 2011), the resolution of T cell 
responses (Zhang and Bevan, 2010; Yang et al., 2012) and the 
choice of T cell fates including T helper cell lineage (Muljo et al., 
2005; Steiner et al., 2011; Baumjohann et al., 2013; Kang et al., 
2013; Khan et al., 2013), the formation of memory cells (Khan 
et al., 2013), and regulatory T cell differentiation (Cobb et al., 
2006; Liston et al., 2008; Zhou et al., 2008; Lu et al., 2010).
Because microRNAs can tune gene expression rather than 
switching expression on or off, they may preferentially affect 
signaling pathways that are sensitive to the dosage of their 
components (Inui et al., 2010). In line with this idea, microRNA 
miR-181a promotes TCR sensitivity in developing thymo-
cytes by targeting phosphatases that counteract TCR signal-
ing (Li et al., 2007). The microRNA effector Ago2 is degraded 
in response to sustained T cell activation (Bronevetsky et al., 
2013) and many 3 UTRs are shortened in activated T cells 
(Sandberg et al., 2008), suggesting that successful T cell activa-
tion may temporarily remove a layer of microRNA control. 
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Figure 1. microRNA deficiency confers increased sensitivity to TCR signals. (a) Irradiated CD45.1 hosts were reconstituted with CD45.2 ERt2Cre 
Dicerwt/wt or ERt2Cre Dicerlox/lox BM. After 8–12 wk, to allow for complete reconstitution, chimeras were given 1 mg tamoxifen i.p. on 5 consecutive days 
and naive CD45.2+ CD4 T cells were isolated 3 wk later. (b) Expression of microRNAs in peripheral CD4 T cells with ERt2Cre-mediated deletion of Dicer. 
Tamoxifen-induced deletion of Dicer1 mRNA in CD4 T cells from ERt2Cre Dicerlox/lox chimeras was around 99% as determined by quantitative RT-PCR 
(mean ± SE; n = 4; normalized to Hprt1; *, P < 0.05), and the expression of Dicer-dependent microRNAs, including miR-16 and Let-7c (mean ± SE; n = 4; 
normalized to sno-135; *, P < 0.05). (c) Naive ERt2Cre Dicerwt/wt (black bars) and ERt2Cre Dicer/ (red bars) CD25 CD62Lhi CD4 T cells were isolated and 
activated with the indicated concentrations of plate-bound anti-TCR+CD28. The percentage of cells expressing CD69 (left) or CD25 (right) was deter-
mined by flow cytometry 24 h later (mean ± SE; n = 4; *, P < 0.05). (d) Expression of Dicer-dependent microRNAs, including miR-16 and Let-7c, after 
CD4Cre-mediated deletion of Dicer (mean ± SE; n = 4; normalized to sno-135; *, P < 0.05). (e) CD4Cre Dicer/ and Dicerlox/lox CD25 CD62Lhi or CD44hi 
CD4 T cells were isolated by cell sorting and activated with the indicated concentrations of plate-bound anti-TCR+CD28. The percentage of cells expres-
sing CD69 was determined by flow cytometry 24 h later (mean ± SE; n = 3). Dicer-deficient CD4 T cells (red bars) were compared with naive (black bars) 
or CD44hi (gray bars) control CD4 T cells (*, P < 0.05). (f) Sensitivity of Dicer-deficient CD4 T cells to cognate peptide-MHC ligands. RAG1/, AND TCR 
transgenic CD4Cre Dicerwt/wt or Dicerlox/lox CD4 T cells were cultured with BM-derived dendritic cells loaded with the indicated concentrations of cognate 
peptide and the percentage of cells expressing CD69 was determined (mean ± SE; n = 3). (g) Left: ERt2Cre Dicerwt/wt and Dicer/ CD4+ CD25 CD62Lhi or 
cells were labeled with CFSE and activated with the indicated concentrations of plate-bound anti-TCR alone (top) or anti-TCR+CD28 (bottom). Cell divi-
sion was assessed 48 h later by CFSE dilution. One representative experiment of 3 is shown. Right: mean ± SE of 3 independent biological replicates.
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a Rag-deficient background. BM-derived APC pulsed with 
graded concentrations of cognate peptide elicited CD69 ex-
pression by significantly higher percentages of Dicer-deficient 
than control CD4 T cells (Fig. 1 f ). This result confirmed height-
ened sensitivity of Dicer-deficient CD4 T cells to physiologi-
cal TCR ligands.
Compared with control CD4 T cells, a greater percentage 
of ERt2Cre Dicer/ CD4 T cells entered the cell cycle and 
completed cell division in response to limiting concentrations 
of anti-TCR in combination with CD28 as judged by the dilu-
tion of CFSE. In marked contrast to control CD4 T cells, highly 
purified Dicer-deficient CD4 T cells proliferated in response 
to plate-bound anti-TCR in the absence of co-stimulation 
(Fig. 1 g). ERt2Cre Dicer/ CD4 T cells proliferated equally 
well in the absence and in the presence of anti-CD28, whereas 
control CD4 T cells depended on co-stimulation for efficient 
proliferation (Fig. 1 g). Co-stimulation–independent pro-
liferation of Dicer-deficient CD4 T cells was confirmed in 
CD4Cre Dicer/ CD4 T cells (unpublished data).
ERt2Cre Dicer/ CD4 T cells produced strikingly higher 
amounts of IL-2 than control ERt2Cre Dicerwt/wt CD4 T cells 
We used a developmentally regulated CD4Cre transgene 
as an additional approach to delete the Dicer locus. Although 
active from the double-positive stage of thymocyte develop-
ment, CD4Cre only depletes microRNA from mature single-
positive thymocytes and peripheral T cells (Muljo et al., 2005; 
Cobb et al., 2006; Fig. 1 d). We sorted naive CD25 CD62Lhi 
CD4 T cells Dicerlox/lox and CD4Cre Dicer/ cells. We also 
isolated Dicerlox/lox CD44hi CD4 T cells for comparison be-
cause CD4Cre Dicer/ CD4 T cells express slightly elevated 
levels of the microRNA target and activation marker CD44. 
At limiting concentrations of anti-TCR, a significantly higher 
percentage of Dicer-deficient CD4 T cells expressed CD69 
(Fig. 1 e) and CD25 (not depicted) than either naive or CD44hi 
control CD4 T cells. Experiments comparing CD4Cre Dicerwt/wt  
versus CD4Cre Dicerlox/lox instead of Dicerlox/lox versus CD4Cre 
Dicerlox/lox CD4 T cells gave indistinguishable results (unpub-
lished data).
To test the sensitivity of Dicer-deficient CD4 T cells to 
peptide–MHC complexes on antigen-presenting cells (APCs) 
we generated mice harboring conditional Dicer alleles, 
CD4Cre and the AND TCR transgene (Kaye et al., 1989) on 
Figure 2. Dicer-deficient CD4 T cells produce IL-2 in the absence of co-stimulation. (a) Naive ERt2Cre Dicerwt/wt and ERt2Cre Dicerlox/lox CD4+ 
CD25 T cells were stimulated with 500 ng/ml plate-bound anti-TCR alone or anti-TCR+CD28. Production IL-2 (left), IFN- (middle), and TNF (right) was 
assessed 48 h later by ELISA (mean ± SE; n = 3). (b) Naive Dicerlox/lox or CD4Cre Dicerlox/lox CD4 T cells were activated with the indicated concentrations of 
plate-bound anti-TCR+CD28. Production IL-2 (left), IFN- (middle), and TNF (right) was assessed 48 h later by ELISA. CD44hi Dicerlox/lox CD4 T cells were 
included as a control (mean ± SE, n = 3). (c) Naive Dicerlox/lox or CD4Cre Dicerlox/lox CD4 T cells were activated with plate-bound anti-TCR alone or anti-
TCR+CD28. Production IL-2 was assessed 48 h later by ELISA (left; mean ± SE; n = 3). The expression of Il2 mRNA was assessed by quantitative RT-PCR at 
0, 4, and 24 h (right, mean ± SE; n = 5, normalized to Hprt1). (d) Dicerlox/lox and CD4Cre Dicerlox/lox mice were injected with anti-CD3 (2C11, 10 µg). 3 h 
later, CD4+ CD25 T cells were purified and Il2 mRNA was quantified by qRT-PCR (mean ± SE; n = 6 mice in 3 independent experiments).
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produce IL-2 upon restimulation. After primary stimulation 
with anti-TCR+CD28, CD4 T cells readily produced IL-2 
upon restimulation (Fig. 3 a) and a substantial amount of IL-2 
was secreted (Fig. 3, b and c). Consistent with the operational 
definition of anergy (Schwartz, 2003), IL-2 production oc-
curred in a reduced percentage of control CD4 T cells that 
had previously been exposed to TCR signals in the absence 
of co-stimulation (Fig. 3 a), and IL-2 secretion was much 
lower (Fig. 3, b and c). In contrast, CD4Cre Dicer/ (Fig. 3, 
a and b) and ERt2Cre Dicer/ CD4 T cells (Fig. 3 c) pro-
duced IL-2 upon restimulation regardless of whether the pri-
mary stimulus consisted of anti-TCR+CD28 or anti-TCR 
alone. Dicer-deficient CD4 T cells exposed to activation by 
anti-TCR alone remained competent to produce not only 
IL-2, but also IFN- and TNF upon restimulation (unpub-
lished data).
Anergy resistance of Dicer-deficient CD4  
T cells is mediated by IL-2
IL-2 receptor signals are required for CD4 T cells to avoid 
anergy (Wells, 2009). We therefore asked whether resistance 
of Dicer-deficient CD4 T cells to anergy relied on IL-2 pro-
duction. When Dicer-deficient CD4 T cells were stimulated 
with anti-TCR in the presence of a neutralization antibody 
to IL-2, subsequent restimulation failed to elicit substantial 
IL-2 production, indicating that anergy had been induced 
(Fig. 3 d). We conclude that Dicer-deficient CD4 T cells es-
cape from anergy by producing IL-2 independently of co-
stimulatory signals.
when they were stimulated with anti-TCR alone or limiting 
concentrations of anti-TCR+CD28 (Fig. 2 a, left). In addition 
to IL-2, Dicer-deficient CD4 T cells also produced significantly 
higher amounts of IFN- (Fig. 2 a, center) and TNF (Fig. 2 a, 
right). To examine cytokine production by Dicer-deficient CD4 
T cells in a different experimental system we used CD4Cre- 
mediated deletion of Dicer (Muljo et al., 2005; Cobb et al., 2006). 
Over a wide range of activation conditions, CD4Cre Dicer/ 
CD25 CD62Lhi CD4 T cells produced significantly more IL-2 
(Fig. 2 b, left), IFN- (Fig. 2 b, center), and TNF (Fig. 2 b, right) 
than naive Dicerlox/lox CD4 T cells or CD44hi Dicerlox/lox CD4 
T cells. Furthermore, CD4Cre Dicer/ CD4 T cells transcribed 
substantial amounts of Il2 mRNA when activated by anti-TCR 
in the absence of co-stimulation (Fig. 2 c, left) and secreted IL-2 
protein at earlier times than control Dicerlox/lox cells (Fig. 2 c, left). 
Dicer-deficient CD4 T cells activated transcription of the Il2 
gene faster (peak at 4 h) than control cells (peak at 24 h) and in 
the absence of co-stimulation (Fig. 2 c, right). Experiments com-
paring CD4Cre Dicerwt/wt versus CD4Cre Dicerlox/lox instead of 
Dicerlox/lox versus CD4Cre Dicerlox/lox CD4 T cells gave indistin-
guishable results (unpublished data). In vivo activation of Dicer-
deficient CD4 T cells also induced significantly higher levels of 
Il2 mRNA (Fig. 2 d). Hence, Dicer-deficient CD4 T cells showed 
heightened sensitivity to TCR signaling and did not require co-
stimulatory signals for IL-2 production or proliferation.
Dicer-deficient CD4 T cells are resistant to the induction  
of anergy by TCR signaling in the absence of co-stimulation
We next addressed the impact of TCR signals in the presence 
or absence of co-stimulation on the ability of CD4 T cells to 
Figure 3. Dicer-deficient CD4 T cells use 
IL-2 to resist anergy induced by TCR sig-
nals in the absence of co-stimulation.  
(a) CD4Cre Dicer/ and Dicerlox/lox CD4+ CD25  
T cells were subjected to primary stimulation 
with plate-bound anti-TCR alone or anti-
TCR+CD28. The cells were restimulated with 
anti-TCR+CD28 and IL-2 production was de-
termined 5h later by intracellular staining and 
flow cytometry (mean ± SE, n = 3 indepen-
dent experiments). (b) CD4Cre Dicer/ and 
Dicerlox/lox CD4+ CD25 T cells were subjected 
to primary stimulation with plate-bound anti-
TCR alone or anti-TCR+CD28. The cells were 
restimulated with anti-TCR+CD28 and IL-2 
production was assessed 48 h later by ELISA 
(mean ± SE, n = 3 independent experiments). 
(c) ERt2Cre Dicerwt/wt and ERt2Cre Dicer/ 
CD4+ CD25 T cells were subjected to pri-
mary stimulation with plate-bound anti-TCR 
alone or anti-TCR+CD28. The cells were re-
stimulated with anti-TCR+CD28 and IL-2 
production was assessed 48 h later by ELISA 
(mean ± SE, n = 4 independent experiments). 
(d) CD4Cre Dicer/ and Dicerlox/lox CD4+ CD25 T cells were stimulated with graded concentrations of plate-bound anti-TCR alone in the presence or the  
absence of neutralizing anti–IL-2. Cells were restimulated with anti-TCR+CD28 and IL-2 production was determined 5 h later (mean ± SE; n = 2 indepen-
dent experiments).
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Figure 4. Posttranscriptional deregulation of the mTOR components Mtor and Rictor and increased mTOR activity in Dicer-deficient CD4  
T cells. (a) CD4Cre Dicer/ and Dicerlox/lox CD4+ CD25 T cells were stimulated in the absence (left) or in the presence (right) of anti-CD28 and immuno-
blotted for pAkt S473, pAkt T308, total Akt and LaminB as a loading control (one representative experiment of 3). (b) CD4Cre Dicer/ and Dicerlox/lox CD4+ 
CD25 T cells were stimulated with anti-TCR in the presence or in the absence of anti-CD28. After 18 h of activation, the percentage of pS6+ cells was 
analyzed either immediately or after resting the cells for 1 or 3 h in the absence of anti-TCR (mean ± SE; n = 3 independent experiments). The inset shows 
pathways to Akt and S6 phosphorylation. (c) CD4Cre Dicer/ and Dicerlox/lox CD4+ CD25 T cells were stimulated for 18 h with anti-TCR (100 ng/ml) and 
the phosphorylation of S6 ribosomal protein (pS6) was determined by intracellular staining and flow cytometry (representative of 3 independent experi-
ments). (d) Statistically significant mRNA expression changes in Dicer-deficient CD4 T cells affect signaling molecules (Storey’s q-value < 0.05). (e) RNA 
was subjected to quantitative RT-PCR using primers specific for spliced (mature) or unspliced (primary) Mtor and Rictor transcripts (mean ± SE; n = 5 
independent experiments, normalized to Hprt1). (f) Quantitative proteomic analysis shows signaling-related protein expression changes in Dicer-deficient 
CD4 T cells. (g) CD4Cre Dicer/ and Dicerlox/lox CD4+ CD25 T cells were analyzed for mTOR, Rictor, and Raptor protein expression (normalized to Lamin B, 
 o
n
 D
ecem
ber 5, 2014
jem.rupress.org
D
ow
nloaded from
 
Published October 13, 2014
JEM Vol. 211, No. 11 
Article
2287
which showed increased expression of mature (spliced) Mtor 
and Rictor transcripts in Dicer-deficient CD4 T cells (Fig. 4 e). 
Quantitative proteomics (Fig. 4 f) showed significantly increased 
Mtor and Rictor protein expression in Dicer-deficient 
CD4 T cells (2.2- and 2.6-fold, respectively; Table S2), which was 
confirmed by Western blotting (Fig. 4 g).
Interestingly, quantitative RT-PCR analysis showed that 
only spliced but not unspliced Mtor and Rictor transcripts were 
up-regulated in Dicer-deficient CD4 T cells (Fig. 4 e). This in-
dicates that the elevated expression of Mtor and Rictor was not 
explained by increased transcription, but rather by the loss of 
post-transcriptional regulation in Dicer-deficient CD4 T cells.
Summarizing the data so far, we find that Dicer-deficient 
CD4 T cells respond to TCR engagement in the absence of 
co-stimulatory signals by producing IL-2, which protects them 
from the induction of anergy and sustains T cell activation 
even after TCR signals are withdrawn (Fig. 4 h). Expression 
profiling at the mRNA and protein levels showed overexpres-
sion of the mTOR complex components Mtor and Rictor, 
which occurred as a result of posttranscriptional, rather than 
transcriptional, deregulation. This was consistent with signal-
ing abnormalities detected in Dicer-deficient T cells; the ac-
tivity of mTORC1 and mTORC2 was elevated as reflected 
by the increased phosphorylation of S6 ribosomal protein and 
Akt S473, respectively.
Elevated expression of mTOR components contributes  
to co-stimulation–independent Il2 expression  
by microRNA-deficient CD4 T cells
Consistent with aberrant S6 and Akt S473 phosphorylation 
described above, the expression of the mTOR components 
Mtor and Rictor was deregulated in Dicer-deficient CD4 
T cells. mTOR and Rictor deregulation occurred at the post-
transcriptional level, suggesting a potential involvement of 
microRNAs. Both Mtor and Rictor are validated microRNA 
targets in cancer cells (Fornari et al., 2010; Nagaraja et al., 2010; 
Uesugi et al., 2011; Tsuruta et al., 2011) and Ago2 CLIP 
experiments had shown that the 3 UTR sequences of Mtor 
and, in particular, Rictor mRNAs are extensively targeted by 
microRNA-containing RISC complexes in activated CD4 
T cells (Loeb et al., 2012; Fig. 5, a and b, left). Based on this in-
formation and on data from heterologous reporter assays in 293 
T cells (Fig. 5, a and b, right) we devised a microRNA sensor 
to probe the impact of endogenous microRNAs on the Mtor 
and Rictor 3UTR in CD4 T cells. This sensor contains a GFP 
reporter linked to the entire Mtor 3UTR or a portion of Rictor 
3UTR (nt 3,000–4,200) and Cherry as an internal control for 
the normalization of GFP fluorescence. GFP-Mtor was de- 
repressed by the mutation of predicted binding sites for Let-7 
and miR-16 (Fig. 5 c). GFP-Rictor 3UTR expression was de-
repressed by mutation of a conserved miR-16–binding site and 
Signaling events in Dicer-deficient CD4 T cells indicate  
a role for deregulated expression of mTOR components
To examine the mechanisms that enable Dicer-deficient CD4 
T to produce IL-2 in the absence of co-stimulation we inves-
tigated signaling events downstream of the TCR. Time course 
analysis of tyrosine phosphorylation 2, 5, and 15 min after 
TCR ligation revealed no abnormalities (unpublished data). 
Ca2+ fluxes appeared slightly blunted in Dicer-deficient CD4 
T cells, but the subsequent dephosphorylation of NFATc1 
and NFATc2 was not substantially reduced or delayed (un-
published data). The TCR-induced phosphorylation of ERK1 
and ERK2 appeared unchanged (unpublished data). Notably, 
however, the phosphorylation of Akt S473 was increased in 
Dicer-deficient CD4 T cells compared with control CD4 
T cells after 2 h of activation with anti-TCR alone (Fig. 4 a, 
left) or with anti-TCR+CD28 (Fig. 4 a, right). pAkt S473 
persisted for extended periods in Dicer-deficient CD4 T cells 
(Fig. 4 a). In contrast, pAkt T308 appeared to be unaffected 
(Fig. 4 a). TCR-induced PI3K activation results in Akt phos-
phorylation of threonine 308 (pAkt T308) by PDK1, whereas 
serine 473 (pS473) is phosphorylated by the mTORC2 
complex (Sarbassov et al., 2006). The elevated and prolonged 
phosphorylation of Akt on S473 therefore indicates increased 
and persistent activation of mTORC2 in Dicer-deficient 
CD4 T cells.
Because Akt is an activator of mTORC1, we analyzed the 
phosphorylation of S6 ribosomal protein (pS6) by S6 kinase 1 
(S6K1), which is a direct downstream target of mTORC1, as 
a proxy for mTORC1 activation (inset, Fig. 4). S6 was phos-
phorylated in a higher percentage of Dicer-deficient than 
control CD4 T cells in response to anti-TCR alone or anti-
TCR+CD28 (Fig. 4 b). When CD4 T cells were activated for 
18 h and subsequently removed from anti-TCR stimulation, 
pS6 persisted for longer in Dicer-deficient than in control CD4 
T cells (Fig. 4 b). The addition of neutralizing IL-2 antibodies 
terminated pS6 upon removal of TCR signals, indicating that 
sustained mTORC1 activity in Dicer-deficient CD4 T cells 
was driven by IL-2 (Fig. 4 c). Hence, mTORC1 and mTORC2 
activation was increased in Dicer-deficient CD4 T cells, and 
was maintained in response to co-stimulation–independent IL-2 
production. Consistent with data that Akt can activate NF-B 
via the degradation of IB (Kane et al., 1999; Ozes et al., 1999), 
TCR stimulation resulted in reduced IB expression and 
increased nuclear cRel translocation in Dicer-deficient CD4 
T cells (unpublished data and this study).
mRNA expression profiling showed that several signaling-
related transcripts were deregulated in Dicer-deficient CD4 
T cells (Fig. 4 d and Table S1). Transcripts encoding the mTOR 
subunits Mtor and Rictor were up-regulated (although not sta-
tistically significant after correction for multiple testing), and 
up-regulation was confirmed by quantitative RT-PCR analysis, 
mean ± SE; n = 5 independent experiments). (h) Dicer-deficient CD4 T cells respond to TCR signals by IL-2 production and proliferation in the  
absence of co-stimulation and escape the induction of anergy in an IL-2–dependent manner. IL-2 sustains T cell activation even after TCR signals 
are withdrawn.
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Figure 5. microRNA regulation of the mTOR components Mtor and Rictor. (a, left) Schematic of the Mtor 3UTR with Ago2 CLIP results (Loeb  
et al., 2012), predicted microRNA-binding sites, and mutations introduced into predicted miR-16 and Let-7 sites (red, numbers indicate nucleotide posi-
tions). (right) 293T cells were cotransfected with firefly luciferase reporter constructs containing the Mtor 3UTR, Renilla luciferase plasmids, and plasmids 
driving the expression of microRNAs predicted to target the Mtor 3UTR (miRecords; Xiao et al., 2009). Firefly over Renilla luciferase ratios were deter-
mined (mean ± SE; n = 3 independent experiments with triplicate wells) and miR-195, miR-16, and Let-7c had statistically significant effects (P < 104;  
P < 0.001; and P < 0.01. (b) Schematic of the Rictor 3UTR with predicted microRNA-binding sites, mutations introduced into a conserved Rictor miR-16 
site (red), and Ago2 CLIP. 293T cells were transfected with firefly luciferase reporter constructs containing 1-kb sections of the Rictor 3UTR along with 
control Renilla luciferase plasmids and plasmids driving the expression of the indicated microRNAs. Firefly over Renilla luciferase ratios were determined 
(mean ± SE; n = 3 independent experiments with triplicate wells) and showed statistically significant effects for miR-16 and Let-7c, the p-values are, 
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heterozygous for Rictor (Rictorlox/wt) but WT for Mtor (Mtorwt/wt; 
unpublished data). This compensatory up-regulation of Rap-
tor was not seen in CD4Cre Dicerlox/lox Mtorwt/wt Rictorwt/wt 
CD4 T cells (Fig. 4 h), in CD4Cre Dicerlox/lox Mtorlox/wt  
Rictor lox/wt CD4 T cells (Fig. 6 b), or in mature Dicer-deficient 
CD4 T cells during acute siRNA-mediated knockdown of 
Rictor (Fig. 7 a). We titrated siRNA oligonucleotides so that 
Rictor protein expression in Dicer-deficient CD4 T cells was 
reduced to levels resembling control CD4 T cells (Fig. 7 a). 
This was sufficient to significantly reduce elevated Akt S473 
phosphorylation (Fig. 7 b), NF-B translocation (Fig. 7 c), 
and co-stimulation–independent IL-2 expression (Fig. 7 d) in 
Dicer-deficient CD4 T cells.
Biological significance
On their own, Dicer-deficient CD4 T cells have limited ca-
pacity as effector cells, as indicated by observations that in the 
absence of T reg cells, Dicer-deficient CD4 T cells cause im-
munopathology with delayed onset compared with WT CD4 
T cells (Cobb et al., 2006). We therefore analyzed the extent 
to which IL-2 produced by Dicer-deficient CD4 T cells can 
influence the decision making by other T cells in a paracrine 
fashion. To determine whether the anergy resistance of Dicer-
deficient CD4 T cells was cell-autonomous we performed 
co-culture experiments. When Thy1.1+ control CD4 T cells 
and Thy1.2+ CD4Cre Dicer/ CD4 T cells were stimulated 
separately with anti-TCR, Dicer-deficient, but not control 
CD4 T cells produced IL-2 upon restimulation (Fig. 8 a). In-
terestingly, when Thy1.1+ control and Thy1.2+ Dicer-deficient 
CD4 T cells were stimulated with anti-TCR in co-culture, 
both Dicer-deficient and control cells produced IL-2 upon 
restimulation (Fig. 8 a). This indicated that Dicer-deficient 
CD4 T cells not only escaped anergy, but also could prevent 
anergy induction in WT CD4 T cells.
To assess the potential relevance of co-stimulation– 
independent IL-2 secretion by Dicer-deficient CD4 T cells 
by an independent approach, we addressed its impact on Il2-
deficient CD4 T cells, which have a severe defect in the ex-
pression of inducible Foxp3 in response to activation in the 
presence of TGF (Fig. 8 b). When activated on their own, 
Il2-deficient CD4 T cells were unable to induce Foxp3, re-
gardless of co-stimulatory signals (Fig. 8 b). Co-culture with 
control CD4 T cells restored Foxp3 induction in Il2-deficient 
CD4 T cells in response to CD3+CD28, but not anti-TCR 
by cotransfection locked nucleic acid (LNA) designed to in-
hibit miR-16, but not a control LNA (Fig. 5 d). Mtor and 
Rictor protein expression were reduced in Dicer-deficient 
CD4 T cells transfected with miR-16 and Let-7c microRNA 
mimics (Fig. 5 e) and increased in control CD4 T cells trans-
fected with LNAs designed to antagonize miR-16 and the 
Let-7 family of microRNAs (Fig. 5 f). Given the length and 
extensive targeting of the Rictor 3 UTR by Ago2 (Loeb et al., 
2012), these experiments are unlikely to be exhaustive, but 
they support a role for endogenous microRNAs including 
miR-16 and Let-7 in modulating Mtor and Rictor expression 
in CD4 T cells.
Collectively, the results of our signaling studies, protein and 
mRNA expression data, and evidence that mTOR compo-
nents are targeted by microRNAs in CD4 T cells, implicated 
Mtor and Rictor as potential mediators of aberrant responses 
to TCR signaling in microRNA-deficient CD4 T cells.
As a genetic approach to address the contribution of Mtor 
and Rictor overexpression, we examined Dicer-deficient 
CD4 T cells that lacked one copy of Mtor and Rictor. The ex-
pression of Mtor and Rictor was elevated in Dicer-deficient 
CD4 T cells, but expression levels were returned to near nor-
mal in CD4Cre Dicerlox/lox Mtorlox/wt Rictorlox/wt CD4 T cells 
(Fig. 6, a and b). Interestingly, heterozygosity in both Mtor and 
Rictor corrected the activation-induced phosphorylation of 
Akt S473 in Dicer-deficient CD4 T cells to near WT levels 
(Fig. 6 c). Remarkably, the co-stimulation–independent ex-
pression of Il2, Ifng, and Tnf mRNA in Dicer-deficient CD4 
T cells and the overproduction of IL-2, IFN-, and TNF 
protein were at least partially corrected by returning Mtor 
and Rictor to near-normal levels (Fig. 6 d). Heterozygosity in 
Mtor and Rictor also reduced the heightened responsiveness of 
Dicer-deficient CD4 T cells to limiting concentrations of 
anti-TCR as assessed by the induction of the activation mark-
ers CD69 and CD25 (P = 0.0063 for CD69; P = 0.0053 for 
CD25; unpublished data). Hence, despite the deregulated ex-
pression of numerous signaling components in Dicer-deficient 
CD4 T cells, correcting the overexpression of Mtor and Ric-
tor was sufficient to significantly redress the key signaling ab-
normalities in these cells.
Although heterozygosity in either Mtor or Rictor alone was 
not sufficient to correct co-stimulation–independent IL-2 
production (data not shown) we noticed that Raptor protein 
expression was elevated in CD4Cre Dicerlox/lox that were 
respectively, for the 1,000–2,000 part: P < 0.05 and P < 0.01; for the 2,000–3,000 part: P < 0.01; and for the 3,000–4,200 part: P < 105. (c) CD4 T cells 
were transfected with GFP constructs containing the WT Mtor 3UTR or Let-7 and/or miR-16–binding site mutants along with Cherry control constructs. 
The ratio of GFP and Cherry fluorescence was determined by flow cytometry (mean ± SE; n = 3 independent experiments). (d) CD4 T cells were transfected 
with GFP constructs containing WT or miR-16 binding site mutant of the Rictor 3UTR (nucleotides 3,000–4,200) in the presence or absence of control or 
mIR-16 family directed LNA as indicated along with Cherry control constructs. The ratio of GFP and Cherry fluorescence was determined by flow cytom-
etry (mean ± SE; n = 3 independent experiments). (e) Dicer-deficient (left) or control (right) CD4 T cells were transfected with the indicated microRNA 
mimics and, 30 h later, the expression of the mTOR components Mtor, Rictor, and Raptor was assessed by immunoblotting in comparison to Dicerlox/lox 
control CD4 T cells (mean ± SE, n = 3 independent experiments, one representative blot is shown). (f) Control (left) or Dicer-deficient (right) CD4 T cells 
were transfected with the indicated LNA oligonucleotides to antagonize endogenous microRNAs and, 30 h later, the expression of mTOR components was 
assessed by immunoblotting in comparison to CD4Cre Dicer/ CD4 T cells (mean ± SE; n = 4 independent experiments, one representative blot is shown).
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derived from Dicer-deficient CD4 T cells can override the 
induction of anergy in control CD4 T cells and restore induc-
ible Foxp3 expression in Il2-deficient CD4 T cells.
alone. In contrast, the presence of Dicer-deficient CD4 T cells 
enabled Il2-deficient CD4 T cells to induce Foxp3 expres-
sion in the absence of co-stimulation (Fig. 8 b). Hence, IL-2 
Figure 6. The deregulated expression of Mtor and Rictor contributes to increased Akt S473 phosphorylation and co-stimulation–independent 
IL-2 production by Dicer-deficient CD4 T cells. (a) Outline of rationale for generating Mtor and Rictor heterozygous CD4 T cells on a Dicer-deficient 
background. (b) Expression of mTOR, Rictor, and Raptor protein in Dicerlox/lox, CD4Cre Dicer/, and CD4Cre Dicer/ Rictor/WT Mtor/WT CD4+ CD25  
T cells (mean ± SE; n = 4 independent experiments). (c) Dicerlox/lox, CD4Cre Dicer/, and CD4Cre Dicer/ Rictor/WT Mtor/WT CD4+ CD25 T cells were acti-
vated with plate-bound anti-TCR (500 ng/ml) in the absence (top) or in the presence (bottom) of anti-CD28 for 0, 2, or 8 h and immunoblotted for pAkt 
S473 and LaminB as a loading control (representative of three independent experiments). (d) Dicerlox/lox, CD4Cre Dicer/, and CD4Cre Dicer/ Rictor/WT 
Mtor/WT CD4+ CD25 T cells were activated with anti-TCR (500 ng/ml). The expression of cytokine mRNA was assessed by quantitative RT-PCR (left;  
mean ± SE; n = 3, normalized to Hprt1) and cytokine secretion was determined by ELISA (right; mean ± SE; n = 3 independent experiments). (top) IL-2; 
(middle) IFN-; (bottom) TNF.
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DISCUSSION
Our findings indicate that the ability of CD4 T cells to dis-
criminate between activating and anergizing stimuli requires 
microRNA-mediated post-transcriptional regulation of the 
mTOR components Mtor and Rictor. To the best of our knowl-
edge, mTOR components had not previously been shown to 
be regulated by microRNAs in the immune system. However, 
Mtor (Nagaraja et al., 2010; Fornari et al., 2010) and Rictor 
(Uesugi et al., 2011; Tsuruta et al., 2011) are validated microRNA 
Figure 7. Partial correction of Akt S473 phosphorylation, nuclear 
translocation of NF-B, and co-stimulation–independent IL-2 pro-
duction by transient knockdown of Rictor in Dicer-deficient CD4  
T cells. (a) siRNA-mediated knockdown of Rictor in Dicer-deficient CD4  
T cells affects Rictor but not Raptor expression (mean ± SE; n = 4 indepen-
dent experiments). (b) Naive CD4Cre Dicer/ and control Dicerlox/lox CD4  
T cells were activated with anti-TCR for 2 h and analyzed by immuno-
blotting with antibodies to Akt, pAkt Ser473; and Lamin B for normalization 
(mean ± SE; n = 3 independent experiments; *, P < 0.05). (c) Naive  
CD4Cre Dicer/ and control Dicerlox/lox CD4 T cells were activated with 
anti-TCR for 3 h and the nuclear translocation cRel was determined  
(ImageStream similarity scores > 0.5; mean ± SE; n = 3 independent experi-
ments). (d) Naive CD4Cre Dicer/ and control Dicerlox/lox CD4 T cells 
treated as in a) were activated with anti-TCR or anti-TCR+CD28 and se-
creted IL-2 was quantified by ELISA after 18 h (mean ± SE; n = 3 indepen-
dent experiments).
Figure 8. Functional relevance of IL-2 produced by Dicer-deficient 
CD4 T cells in the absence of co-stimulation. (a) Resistance of Dicer-
deficient CD4 T cells to anti-TCR–induced anergy is contagious. Thy1.1+ 
control and Thy1.2+ CD4Cre Dicer/ CD4+ CD25 T cells were cultured 
either alone or as a mixture (mix) on plate-bound anti-TCR (500 ng/ml, 
left; graded concentrations, right). IL-2 production was determined 5 h 
after restimulation with anti-TCR+CD28 using Thy1.1 to distinguish con-
trol CD4 T cells from Dicer-deficient CD4 T cells (mean ± SE; n = 2 inde-
pendent experiments). (b) CD45.1 Il2-deficient CD4 T cells were activated 
with anti-TCR alone or with anti-CD3+CD28 in the presence of TGF-  
(1 ng/ml). Where indicated, cultures were supplemented with CD45.2 control 
or Dicer-deficient CD4 T cells. Il2-deficient CD4 T cells alone were unable 
to induce Foxp3. In the presence of co-stimulatory signals, both control 
and Dicer-deficient CD4 T cells could rescue Foxp3 induction in Il2-deficient 
CD4 T cells. In the absence of co-stimulation, only Dicer-deficient CD4 T cells 
were able to facilitate Foxp3 induction in Il2-deficient CD4 T cells  
(mean ± SEM; n = 3 independent experiments).
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a feed-forward loop exists between the intracellular PI3K–Akt–
mTOR signaling network and the production of the extra-
cellular signaling molecule IL-2. The result of this feed-forward 
loop is self-sustaining network activity, which is interrupted 
when extracellular IL-2 is neutralized.
A fundamental insight of the work presented here is that the 
deregulated expression of Mtor and Rictor contributes sig-
nificantly to the increased mTOR activity observed in response 
to TCR stimulation of Dicer-deficient CD4 T cells. Hence, 
the biochemical and functional activity of mTOR, especially 
mTORC2, is restrained by microRNA-mediated regulation 
of Mtor and Rictor expression. Increased mTORC2 activity 
led to increased IL-2 production in Dicer-deficient cells. To 
what extent mTOR becomes biochemically rate limiting when 
the expression of mTOR components is reduced to lower than 
normal levels may be condition dependent. Published results 
suggest either a decrease or no apparent change in IL-2 pro-
duction when Rictor expression is reduced genetically (Lee 
et al., 2010; Delgoffe et al., 2011) and the up-regulation of 
Raptor we observe after CD4Cre-mediated deletion of Rictor 
suggests the potential for compensatory mechanisms during 
T cell development.
Although previous work on the regulation of T cell an-
ergy had emphasized the importance of E3 ligases that con-
nect the activation of signaling components to their proteolytic 
degradation in the immune system (Paolino and Penninger, 
2010), our data makes the point that the controlled produc-
tion of signaling components, not just their degradation, con-
tributes to activation versus anergy discrimination.
Autoimmunity and immune pathology in microRNA-
deficient mice may be attributable not just to T cell activation 
in the absence of co-stimulation, but also to reduced regulatory 
T cell numbers and activity (Cobb et al., 2006; Chong et al., 
2008; Liston et al., 2008; Zhou et al., 2008; Lu et al., 2010), 
overproduction of IFN- linked to the T-box transcription fac-
tors and miR-29 targets T-bet and Eomes (Steiner et al., 2011), 
and TNF, which is controlled by miR-146a via TRAF6, IRAK, 
RelB, and NF-B pathway activation (Taganov et al., 2006). 
The severity of the resulting phenotypes is limited because 
microRNA-deficient T cells show poor long-term effector 
function and survival (Cobb et al., 2005; Muljo et al., 2005; 
Chong et al., 2008; Liston et al., 2008; Zhou et al., 2008; 
Steiner et al., 2011).
Previous studies had linked mTOR activation to anergy 
by demonstrating that the mTOR inhibitor rapamycin causes 
CD4 T cell anergy irrespective of co-stimulation (Powell et al., 
1999; Mondino and Mueller, 2007; Powell and Delgoffe, 2010). 
In considering the interplay between Dicer and the mTOR 
pathway in CD4 T cells, it is noteworthy that rapamycin treat-
ment can restore an anergic state to Dicer-deficient CD4 T cells 
(unpublished data) despite the elevation of Mtor and Rictor 
protein levels. Of note, prolonged (>8 h) rapamycin treatment 
of WT CD4 T cells eliminated their capacity for TCR/CD28-
induced Akt S473 phosphorylation, which is indicative of 
reduced mTORC2 activity (Sarbassov et al., 2006; Lee et al., 
2010; Delgoffe et al., 2011). Rapamycin also diminished the 
targets in cancer, where deregulated mTOR activity contrib-
utes to cellular survival and proliferation. The 3UTR of Rictor 
in particular is extensively targeted by Ago-2 containing RISC 
complexes in CD4 T cells (Loeb et al., 2012) and our experi-
ments show that miR-16 and Let-7 family members are among 
the microRNAs that regulate Mtor and Rictor expression.
Co-stimulation–independent IL-2 production is central 
to the phenotype of Dicer-deficient CD4 T cells, and linked 
to increased phosphorylation of Akt by overexpression of 
Rictor and Mtor. Transcription of Il2 is regulated by integra-
tion of signals that emanate from the TCR and co-stimulatory 
receptors such as CD28 and converge on the Il2 locus through 
NF-B, NF-AT, and AP-1 (Kane et al., 2001; Mondino and 
Mueller, 2007). Akt is upstream of mTORC1 and down-
stream of mTORC2 (Sarbassov et al., 2006) and in its activated 
state may replace CD28 signals in the transcriptional regula-
tion of Il2 through the Carma1–Bcl10–Malt1 (CBM) complex 
(Kane et al., 1999). In addition to Akt, mTORC2 regulates 
PKC (Lee et al., 2010), and together PKC and Akt facilitate 
the nuclear translocation of NF-B, which drives Il2 expres-
sion in association with NF-AT and AP-1 (Kane et al., 2001; 
Mondino and Mueller, 2007). Once initiated, IL-2 production 
can perpetuate T cell activation, and we have shown that IL-2 
prolongs the pS6 and pAkt S473 phosphorylation in Dicer-
deficient CD4 T cells, even when TCR signals are withdrawn. 
Persistent mTORC1 activation correlates with successful T cell 
activation and supports the increased metabolic demands of T cell 
activation, proliferation, and the acquisition of effector functions 
(Thompson and Jones, 2007). Importantly, co-stimulation– 
independent IL-2 production not only allows Dicer-deficient 
CD4 T to escape anergy and to proliferate in an autocrine 
fashion, but also acts in a paracrine fashion to enable WT CD4 
T cells to avoid anergy in the absence of co-stimulatory signals, 
and to allow Foxp3 induction in Il2-deficient CD4 T cells.
Regulation by microRNAs is often combinatorial, with 
multiple microRNAs regulating multiple targets. In some cases, 
however, individual microRNA targets can be identified that 
account for micro-RNA-dependent phenotypes (Li et al., 
2007; Xiao et al., 2007). Mtor and Rictor are by no means the 
only signaling components deregulated in Dicer-deficient CD4 
T cells (Fig. 6, a and b). Nevertheless, our experiments with 
Rictor and Mtor compound heterozygous, Dicer-deficient CD4 
T cells provide a striking demonstration that the microRNA 
targets Rictor and Mtor are key to co-stimulation–independent 
IL-2 production. Correcting the elevated expression of Mtor 
and Rictor was sufficient to alleviate increased Akt S473 phos-
phorylation and co-stimulation–independent IL-2 produc-
tion in Dicer-deficient CD4 T cells. This result indicates that 
the deregulated expression of mTOR components is a major 
contributor to co-stimulation–independent IL-2 production 
in Dicer-deficient CD4 T cells.
In signaling networks, individual components, or nodes, can 
be critical for network output, in particular nodes with inte-
grator function such as mTOR complexes. microRNAs and 
their target mRNAs frequently participate in feed-forward 
regulation (Tsang et al., 2007). In the scenario described here, 
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Dicer/ and Dicerlox/lox control CD4 T cells were freshly isolated ex vivo and 
therefore contained arginine and lysine with normal light (12C) carbons and 
(14N) nitrogens. Incorporation of labeled amino acids was verified as previously 
described (Graumann et al., 2008). Cell lysates were prepared as previously de-
scribed (Graumann et al., 2008) and EL4 cell lysates were mixed 1:1 with either 
CD4Cre Dicer/ or Dicerlox/lox control CD4 T cell extracts, processed, gel frac-
tionated, in-gel digested, and subjected to isoelectric focusing of peptides and 
high resolution analysis on a linear ion trap-orbitrap instrument (LTQ-Orbitrap) 
as previously described (Graumann et al., 2008). Mass spectra were acquired using 
Xcalibur software and analyzed using MaxQuant (Cox and Mann, 2008; version 
1.0.4.11) with a false positive rate of 5% at the peptide level and 1% at the protein 
level. Peptide ratios between heavy EL4 cells and either light CD4Cre Dicer/ 
or Dicerlox/lox control CD4 T cells to derive a ratio of ratios between CD4Cre 
Dicer/ and Dicerlox/lox control CD4 T cells. Annotations were extracted from 
the European Bioinformatics Institute Gene Ontology Annotation (GOA) 
Mouse 36.0 release containing 34,888 proteins.
Quantitative RT-PCR. Total RNA was isolated using RNAbee (AMS Bio-
tech) and reverse transcribed using Superscript III (Invitrogen). Real-time 
PCR analysis was performed on an Opticon DNA engine (MJ Research 
Inc.). The dissociation curve was analyzed for each sample. Relative level of 
the target sequence against the reference sequence was calculated using the 
 cycle threshold method. Primer sequences were as follows: Hprt1 forward, 
5-TCAGTCAACGGGGGACATAAA-3, Hprt1 reverse 5-GGGGCT-
GTACTGCTTAACCAG-3; Il2 forward, 5-GTGCCTAGAAGATGAAC-
TTGGA-3, Il2 R 5-AAATGTGTTGTCAGAGCCCT-3, Dicer1 forward, 
5-TATCGCCTTCACTGCCTTCT-3 Dicer1 reverse, 5-TTTTCCACCC-
GAAGTCTAAGTT-3; spliced Mtor forward 5-ACCGGCACACATTT-
GAAGAAG-3 Mtor reverse, 5-CTCGTTGAGGATCAGCAAGG-3; 
spliced Rictor forward, 5-ACCGACACCATCACCATGAAG-3 Rictor re-
verse, 5-GACACCATAGACCTAACTGAGGA-3; unspliced Mtor forward, 
5-TACCGGGTGAGAGATGGGTC-3 Mtor reverse, 5-CACAGTGA-
GCAGGAGAGAG-3; unspliced Rictor, forward 5-TGGTGGTAAA-
AGAGTGGC-3 Rictor reverse 5-GTGTAAGTCAGAGGACGG-3. micro-
RNAs were quantified using miScript RT and qPCR kits according to the 
manufacturer’s instructions (QIAGEN).
Reporter constructs. The full-length 3UTRs of mTOR and Rictor were 
amplified from genomic DNA (Mtor forward 5-CTGAGGCCTGGAA-
AACCACGTCGTCTCC-3, reverse 5-TATGCTTTTAAAATTCTGATG-
TCATTTATTGG-3; Rictor forward 5-CCTCATGCTTATGACGTT-
TATAGCTGG-3, reverse 5-AAGAATTTTAAGTACATTTTATTAACA-
ATG-3) and cloned into pmaxGFP (Amaxa) or pRL (Promega). Mutants 
were made by site directed mutagenesis using the primers: Mtor let-7 site 
5-CCACTATCCTGTTtggagaACCCGTCCCTGG-3, miR-16 site 5-CC-
AACCTCCTAGCTcgacgaGAAAAGACACTGTC-3, Rictor miR-16 site 
in 3,000–4,200 fragment 5-GACCTTTTTTTTTTTTTTTTTAGTA-
ATACcgacgatCATTTTTGGAGG-3. A pmaxCherry plasmid was used as a 
transfection control.
Luciferase assays. Control or 3UTR bearing Firefly constructs alongside 
Renilla control plasmids were transfected into 293T cells. Cells were cotrans-
fected with empty or microRNA containing MIG plasmid. Luciferase lumi-
nescence was determined 36 h later. Ratios between Firefly and Renilla were 
normalized to the ratios obtained when the empty MIG plasmid was used.
miRNA mimics and LNAs. miRNA mimics (miRIDIAN) supplied by 
Thermo Scientific and used according to manufacturer instructions. LNAs 
targeting miRNA family seed sequences (Exiqon) were designed and used as 
described (Obad et al., 2011).
Online supplemental material. Table S1 shows differentially expressed 
signaling-related mRNAs in Dicer-deficient CD4 T cells identified by gene 
expression arrays. Table S2 shows differentially expressed signaling-related 
proteins in Dicer-deficient CD4 T cells identified by quantitative proteomics. 
Table S3 shows densitometry values of scanned western blots. Online 
phosphorylation of Akt on S473 phosphorylation in human 
Jurkat T cells in vitro and in mouse thymocytes in vivo 
(Sarbassov et al., 2006), suggesting that rapamycin could exert 
its effect as an immunosuppressant in part by establishing an 
anergic state in vivo. However, the overall impact of rapamycin- 
induced anergy in conventional CD4 T cells may be counter-
balanced by a decrease in mTOR-dependent T reg cell activity 
(Procaccini et al., 2010; Zeng et al., 2013).
MATERIALS AND METHODS
Mice, flow cytometry, cell sorting, and culture. Animal work was per-
formed under a UK Home Office Project Licence according to the Animals 
(Scientific Procedures) Act, UK. Mice carrying floxed Dicer (Cobb et al., 2005) 
or mTOR (Risson et al., 2009) alleles in combination with CD4Cre or 
ERt2Cre transgenes on a mixed C57BL/129 background and Thy1.1 congenic 
C57BL/6 mice were maintained under specific pathogen–free conditions.
For the generation of BM chimeras, C57BL/6 CD45.1 x CD45.2 mice 
were lethally irradiated and reconstituted i.v. with a mixture of T cell–depleted 
IL2KO CD45.1 and either Dicer lox/lox or CD4Cre Dicerlox/lox CD45.2 BM 
cells. In a separate set of experiments, C57BL/6 CD45.1 irradiated recipient 
were reconstituted with ERt2Cre+ Dicerwt/wt or ERt2Cre+ Dicerlox/lox CD45.2 
BM cells. Chimeras were analyzed 8–12 wk after reconstitution. Deletion of 
Dicer was induced by injection of ERt2Cre+ Dicerwt/wt or ERt2Cre+ 
Dicerlox/lox mice, ERt2Cre+ Dicerwt/wt or ERt2Cre+ Dicerlox/lox chimeras 1 mg 
tamoxifen i.p. twice daily for 5 d. Analysis was done on day 21.
Cells were stained, analyzed, and sorted on Calibur, DIVA, or Aria flow cy-
tometers (BD) as previously described (Cobb et al., 2005). In some experiments, 
cells were sorted using magnetic beads (Miltenyi Biotec). Antibodies used 
were as follows: CD25-PE, CD25-APC, CD69-FITC, CD62L-PE Thy1.1-
biotin, anti–IL-2 PE, anti–IFN- APC, anti-TNF FITC (BD), CD4-TC (Invit-
rogen); pS6 (Cell Signaling Technology) anti-Rabbit Ig FITC (Invitrogen).
Anergy was induced by stimulation on anti-TCR–coated plates in the 
absence of anti-CD28. Cells were replated after 24 h, allowed to rest for 
24 h, and restimulated for 5 h. Cytokine production was measured by intra-
cellular staining or by ELISA.
T cell activation in vivo was induced by intraperitoneal injection of anti-
CD3 (10 µg, 2C11; eBioscience). For CFSE labeling, 5–10 × 106 cells/ml 
were incubated for 8 min at 37°C with 10 µg/ml of CFSE in PBS.
For intracellular staining, 1–2 × 105 T cells were stimulated for 5 h in flat 
bottom 96-well plates coated with 500 ng/ml anti-TCR (H57) and 2 µg/ml 
soluble anti-CD28 (BD) in the presence of Golgi-stop, permeabilized with 
Cytofix/Cytoperm (BD) and stained with the indicated antibodies. Where 
indicated, recombinant IL-2 (R&D Systems) was used at 5 ng/ml and anti–
IL–2 (S4B6; BD) at 10 µg/ml.
ELISA. IL-2, IFN-, and TNF were measured by ELISA according to the 
supplier’s instructions (R&D Systems).
Immunoblotting. Standard immunoblotting techniques were used with 
the following antibodies: phosphotyrosine (4G10; EMD Millipore), Lamin B 
(C20; Santa Cruz Biotechnology, Inc.), phosphoAkt Thr308 (244F9, 4056), 
phosphoAkt Ser473 (9271), Akt1 (2H10, 2967), mTOR (7C10), Rictor 
(53A2), and Raptor (24C12; Cell Signaling Technology). Blots were quanti-
fied using fluorescent secondary antibodies and an Odyssey system (Licor).
Proteomics. The mouse T cell line EL4 was labeled for five passages in 
Dulbecco’s modified Eagle’s medium (Invitrogen) devoid of arginine and ly-
sine and supplemented with 10% dialyzed fetal bovine serum (Invitrogen, 
26400–044); 3.5 mg/ml glucose (to a final concentration of 4.5 mg/ml); 0.1 mm 
nonessential amino acids without arginine, lysine, and proline; 100 U/ml penicil-
lin/streptomycin (Invitrogen); 2 mm Glutamax (Invitrogen); 100 -mercapto-
ethanol (Sigma-Aldrich) and arginine and lysine with heavy (13C) carbons and 
(15N) nitrogens (Arg10; Cambridge Isotope Laboratories; Lys8, Cambridge Iso-
tope Laboratories) at 28 µg/ml for arginine and 49 µg/ml for lysine. CD4Cre 
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Table S1. Differentially expressed signaling-related mRNAs in Dicer-deficient CD4 
T cells identified by gene expression arrays 
 
 
Signalling-related transcripts, up-regulated (q<0.05) 
   
Gene 
Symbol 
Gene 
Name 
F-C 
(log2) GO-ID 
 
Gpr114 G protein-coupled receptor 114 3.30 GO:0007165 
Iigp1 interferon inducible GTPase 1 3.11 GO:0019221 
Ifitm3 interferon induced transmembrane protein 3 1.71 GO:0060337 
Nedd4 
neural precursor cell expressed developmentally down-regulated 
gene 4 1.66 GO:0014068 
Pde2a phosphodiesterase 2A, cGMP-stimulated 1.38 GO:0007165 
Itgb3 integrin beta 3 1.33 GO:0007229 
Abca1 ATP-binding cassette, sub-family A (ABC1), member 1 1.31 GO:0007186 
Irf1 interferon regulatory factor 1 1.30 GO:0007249 
Stat1 signal transducer and activator of transcription 1 1.29 GO:0007259 
Txnip thioredoxin interacting protein 1.22 GO:0048008 
Il10rb interleukin 10 receptor, beta 1.21 GO:0019221 
Nr1d1 nuclear receptor subfamily 1, group D, member 1 1.20 GO:0034144 
Arpp19 cAMP-regulated phosphoprotein 19 1.17 GO:0046579 
Tgfbr1 transforming growth factor, beta receptor I 1.17 GO:0007165 
Cacnb3 calcium channel, voltage-dependent, beta 3 subunit 1.10 GO:0050852 
Sept2 septin 2 1.07 GO:0007224 
Tgfbr3 transforming growth factor, beta receptor III 1.07 GO:0007179 
Sgk1 serum/glucocorticoid regulated kinase 1 1.05 GO:0043402 
Igfbp4 insulin-like growth factor binding protein 4 1.01 GO:0043410 
Tlr1 toll-like receptor 1 0.98 GO:0007165 
Aplp2 amyloid beta (A4) precursor-like protein 2 0.97 GO:0007176 
Rab1 RAB1, member RAS oncogene family 0.96 GO:0007264 
Bcl3 B-cell leukemia/lymphoma 3 0.96 GO:0007249 
Ctnnb1 catenin (cadherin associated protein), beta 1 0.90 GO:0003136 
Nfe2l2 nuclear factor, erythroid derived 2, like 2 0.90 GO:0030968 
Ifnar1 interferon (alpha and beta) receptor 1 0.90 GO:0019221 
Rab12 RAB12, member RAS oncogene family 0.87 GO:0007264 
Smurf2 SMAD specific E3 ubiquitin protein ligase 2 0.87 GO:0030579 
Mknk2 MAP kinase-interacting serine/threonine kinase 2 0.86 GO:0007243 
Msh6 mutS homolog 6 (E. coli) 0.85 GO:0008630 
Rab2a RAB2A, member RAS oncogene family 0.85 GO:0007264 
Adam10 a disintegrin and metallopeptidase domain 10 0.84 GO:0007219 
Sema7a 
sema domain, immunoglobulin domain (Ig), and GPI membrane 
anchor, (semaphorin) 7A 0.81 GO:0007229 
Itgb7 integrin beta 7 0.81 GO:0007229 
Dyrk2 dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 0.81 GO:0007224 
Hspa5 heat shock protein 5 0.78 GO:0006983 
Sel1l sel-1 suppressor of lin-12-like (C. elegans) 0.77 GO:0007219 
 2 
Adamts14 
a disintegrin-like and metallopeptidase (reprolysin type) with 
thrombospondin type 1 motif, 14 0.77 GO:0007229 
Psap prosaposin 0.76 GO:0043408 
Spnb2 spectrin beta 2 0.76 GO:0007182 
Arl8b ADP-ribosylation factor-like 8B 0.76 GO:0007264 
Pecam1 platelet/endothelial cell adhesion molecule 1 0.75 GO:0007266 
Stat3 signal transducer and activator of transcription 3 0.75 GO:0007165 
Calr calreticulin 0.75 GO:0033144 
Mcl1 myeloid cell leukemia sequence 1 0.74 GO:2001240 
Il21r interleukin 21 receptor 0.73 GO:0007165 
Pik3cd phosphatidylinositol 3-kinase catalytic delta polypeptide 0.73 GO:0007166 
Itgav integrin alpha V 0.72 GO:0007229 
Ddx58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 0.72 GO:0039529 
Adcy6 adenylate cyclase 6 0.71 GO:0007212 
Gsn gelsolin 0.71 GO:0048015 
Gata3 GATA binding protein 3 0.71 GO:0007165 
Nptn neuroplastin 0.70 GO:0045743 
Ppp1r9b protein phosphatase 1, regulatory subunit 9B 0.70 GO:2000474 
Itgb2 integrin beta 2 0.69 GO:0007229 
Jak1 Janus kinase 1 0.68 GO:0007167 
Smad5 MAD homolog 5 (Drosophila) 0.67 GO:0007179 
Tgfbr2 transforming growth factor, beta receptor II 0.67 GO:0007178 
Cd4 CD4 antigen 0.67 GO:0007166 
Ccr7 chemokine (C-C motif) receptor 7 0.64 GO:0007165 
Hbp1 high mobility group box transcription factor 1 0.64 GO:0016055 
Igf2r insulin-like growth factor 2 receptor 0.64 GO:0007186 
Arhgef6 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 0.62 GO:0035023 
Rras2 related RAS viral (r-ras) oncogene homolog 2 0.62 GO:0007165 
Tnks2 
tankyrase, TRF1-interacting ankyrin-related ADP-ribose 
polymerase 2 0.62 GO:0016055 
Stk4 serine/threonine kinase 4 0.61 GO:0007165 
Ece1 endothelin converting enzyme 1 0.61 GO:0045745 
Dnaja1 DnaJ (Hsp40) homolog, subfamily A, member 1 0.60 GO:0030521 
Nfkbia 
nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor, alpha 0.59 GO:0007253 
Rac1 RAS-related C3 botulinum substrate 1 0.58 GO:0007264 
Gpr18 G protein-coupled receptor 18 0.57 GO:0007165 
Rab18 
RAB18, member RAS oncogene family | fatty acid binding 
protein 5-like 2 0.57 GO:0007264 
Ecm1 extracellular matrix protein 1 0.57 GO:0001960 
Dusp10 dual specificity phosphatase 10 0.56 GO:0000188 
Adam17 a disintegrin and metallopeptidase domain 17 0.56 GO:0007173 
Pik3r1 
phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 
(p85 alpha) 0.56 GO:0007165 
Atp2a2 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 0.55 GO:0006984 
Nfkb2 
nuclear factor of kappa light polypeptide gene enhancer in B-
cells 2, p49/p100 0.54 GO:0007165 
Ubash3a ubiquitin associated and SH3 domain containing, A 0.54 GO:0050860 
G3bp2 GTPase activating protein (SH3 domain) binding protein 2 0.53 GO:0007264 
Gng12 guanine nucleotide binding protein (G protein), gamma 12 0.53 GO:0007165 
 3 
Lck lymphocyte protein tyrosine kinase 0.52 GO:0007166 
Sh3glb1 SH3-domain GRB2-like B1 (endophilin) 0.52 GO:0007165 
Sema4d 
sema domain, immunoglobulin domain (Ig), transmembrane 
domain (TM) and short cytoplasmic domain, (semaphorin) 4D 0.52 GO:0014068 
Rap1b RAS related protein 1b similar to GTP-binding protein 0.51 GO:0007165 
Ksr1 kinase suppressor of ras 1 0.50 GO:0035556 
Zc3hav1 zinc finger CCCH type, antiviral 1 0.47 GO:0043123 
Lats1 large tumor suppressor 0.47 GO:0009755 
Bnip2 BCL2/adenovirus E1B interacting protein 1, NIP2 0.46 GO:0043410 
Gna13 guanine nucleotide binding protein, alpha 13 0.45 GO:0007165 
Hif1a hypoxia inducible factor 1, alpha subunit 0.45 GO:0007165 
Grhl3 grainyhead-like 3 (Drosophila) 0.45 GO:0090179 
Ncoa3 nuclear receptor coactivator 3 0.45 GO:0033145 
Socs3 suppressor of cytokine signaling 3 0.45 GO:0007165 
Aars alanyl-tRNA synthetase | exosome component 6 0.45 GO:0030968 
Prkca protein kinase C, alpha 0.44 GO:0000188 
Slc44a2 solute carrier family 44, member 2 0.44 GO:0007165 
Lfng LFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase 0.43 GO:0045747 
Sirt1 sirtuin 1 (silent mating type information regulation 2, homolog) 1  0.42 GO:0008630 
Nrbp1 nuclear receptor binding protein 1 0.42 GO:0007254 
Rps6ka5 ribosomal protein S6 kinase, polypeptide 5 0.42 GO:0007243 
Vav2 vav 2 oncogene 0.42 GO:0007264 
Itgal integrin alpha L 0.42 GO:0007166 
Cflar CASP8 and FADD-like apoptosis regulator 0.41 GO:2001237 
Ppp2r5a protein phosphatase 2, regulatory subunit B (B56), alpha isoform 0.41 GO:0007165 
Mapk1 mitogen-activated protein kinase 1 0.40 GO:0000165 
Ripk1 receptor (TNFRSF)-interacting serine-threonine kinase 1 0.40 GO:0007165 
P2rx4 purinergic receptor P2X, ligand-gated ion channel 4 0.40 GO:0007165 
Arf1 ADP-ribosylation factor 1 0.40 GO:0007264 
Rhot1 ras homolog gene family, member T1 0.39 GO:0007264 
Asb8 ankyrin repeat and SOCS box-containing protein 8 0.39 GO:0035556 
Tlr6 toll-like receptor 6 0.39 GO:0002224 
Crk v-crk sarcoma virus CT10 oncogene homolog (avian) 0.38 GO:0035020 
Tbl1xr1 transducin (beta)-like 1X-linked receptor 1 0.38 GO:0060070 
Med14 mediator complex subunit 14 0.37 GO:0030518 
Rhoa ras homolog gene family, member A 0.37 GO:0007229 
Il12rb1 interleukin 12 receptor, beta 1 0.37 GO:0035722 
Nfkb1 
nuclear factor of kappa light polypeptide gene enhancer in B-
cells 1, p105 0.36 GO:0007165 
Plcl2 phospholipase C-like 2 0.36 GO:0007165 
Pak2 p21 (CDKN1A)-activated kinase 2 0.36 GO:2001238 
Smarcc1 
SWI/SNF related, matrix associated, actin dependent regulator 
of chromatin, subfamily c, member 1 0.35 GO:0008286 
Csnk2a1 casein kinase 2, alpha 1 polypeptide 0.34 GO:0016055 
Asb3 ankyrin repeat and SOCS box-containing protein 3 0.34 GO:0035556 
Ldb1 LIM domain binding 1 0.33 GO:0016055 
Socs7 suppressor of cytokine signaling 7 0.32 GO:0008286 
Aak1 AP2 associated kinase 1 0.32 GO:0045747 
Dot1l DOT1-like, histone H3 methyltransferase (S. cerevisiae) 0.31 GO:0046425 
Ppap2b phosphatidic acid phosphatase type 2B 0.31 GO:0030111 
 4 
Adcy7 adenylate cyclase 7 0.31 GO:0035556 
Vapa vesicle-associated membrane protein, associated protein A 0.31 GO:0007165 
Gpsm2 G-protein signalling modulator 2 (AGS3-like, C. elegans) 0.30 GO:0007165 
Ncstn nicastrin 0.30 GO:0007219 
Cdc42 cell division cycle 42 homolog (S. cerevisiae) 0.29 GO:0007264 
Rab10 RAB10, member RAS oncogene family 0.29 GO:0007264 
Rnf14 ring finger protein 14 0.28 GO:0060765 
Casp2 caspase 2 0.25 GO:0006977 
Map3k4 mitogen-activated protein kinase kinase kinase 4 0.25 GO:0007243 
Nras neuroblastoma ras oncogene 0.25 GO:0007265 
Prkd2 protein kinase D2 0.22 GO:0007243 
Mapkapk5 MAP kinase-activated protein kinase 5 0.22 GO:0007265 
Hdac4 histone deacetylase 4 0.19 GO:0010882 
Hipk3 homeodomain interacting protein kinase 3 0.19 GO:0043508 
Stat5a signal transducer and activator of transcription 5A 0.19 GO:0007165 
Raf1 v-raf-leukemia viral oncogene 1 0.15 GO:0000165 
Vmn2r20 vomeronasal 2, receptor 20 0.12 GO:0007165 
Golph3 golgi phosphoprotein 3 0.11 GO:0032008 
Olfr919 olfactory receptor 919 0.10 GO:0007165 
 Signalling related genes, down-regulated (q-value < 0.05)   
Gene 
Symbol 
Gene 
Name 
F-C 
(log2) GO-ID 
    
Olfr628 olfactory receptor 628 -0.06 GO:0007165 
Olfr1242 olfactory receptor 1242 -0.08 GO:0007165 
Scg2 secretogranin II -0.10 GO:0000165 
Gpr15 G protein-coupled receptor 15 -0.10 GO:0007165 
Guca1a guanylate cyclase activator 1a (retina) -0.10 GO:0007602 
Sept4 septin 4 -0.12 GO:2001244 
Arl10 ADP-ribosylation factor-like 10 -0.14 GO:0007264 
Nmu neuromedin U -0.15 GO:0007218 
Klk1b4 kallikrein 1-related pepidase b4 -0.16 GO:0007264 
Olfr1427 olfactory receptor 1427 -0.16 GO:0007165 
Olfr669 olfactory receptor 669 -0.17 GO:0007165 
Nphs1 nephrosis 1 homolog. nephrin (human) -0.18 GO:0000165 
Carm1 coactivator-associated arginine methyltransferase 1 -0.18 GO:0030518 
Sox2 SRY-box containing gene 2 -0.19 GO:0030178 
Baiap2l2 BAI1-associated protein 2-like 2 -0.19 GO:0007165 
Htt huntingtin -0.21 GO:0007212 
Cdkn2b cyclin-dependent kinase inhibitor 2B (p15. inhibits CDK4) -0.23 GO:0030511 
Olfr95 olfactory receptor 95 -0.25 GO:0007165 
Robo1 roundabout homolog 1 (Drosophila) -0.28 GO:0035385 
Gabrr2 gamma-aminobutyric acid (GABA-C) receptor. subunit rho 2 -0.28 GO:0007214 
Il20rb interleukin 20 receptor beta -0.30 GO:0002765 
Irak1 interleukin-1 receptor-associated kinase 1 -0.31 GO:0001959 
Ppp2r1b 
protein phosphatase 2 (formerly 2A). regulatory subunit A (PR 
65). beta isoform -0.34 GO:2001241 
 5 
Ppp2r5c 
protein phosphatase 2. regulatory subunit B (B56). gamma 
isoform -0.36 GO:0006977 
Rcan3 regulator of calcineurin 3 -0.38 GO:0019722 
Efnb3 ephrin B3 -0.40 GO:0048013 
Kcnh2 
potassium voltage-gated channel. subfamily H (eag-related). 
member 2 -0.42 GO:0000160 
Mif macrophage migration inhibitory factor -0.43 GO:0007166 
Tmbim4 transmembrane BAX inhibitor motif containing 4 -0.45 GO:0050848 
Egr1 early growth response 1 -0.49 GO:0030509 
S100a13 S100 calcium binding protein A13 -0.50 GO:0043123 
Srebf2 sterol regulatory element binding factor 2 -0.54 GO:0035104 
Timp2 tissue inhibitor of metalloproteinase 2 -0.80 GO:0032487 
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Table S2. Differentially expressed signaling-related proteins in Dicer-deficient CD4 
T cells identified by quantitative proteomics 
Gene Protein F-C GO-ID 
Signalling-related proteins up-regulated >1.5 fold 
Itgb3 Integrin beta-3 5.22 GO:0007229 
Hgs Hepatocyte growth factor-regulated tyrosine kinase substrate 4.33 GO:0046426 
Rasa1 RAS p21 protein activator 1 4.28 GO:0007165 
Crk v-crk sarcoma virus CT10 oncogene homolog 4.19 GO:0035020 
Iqgap2 IQ motif containing GTPase activating protein 2 3.59 GO:0007165 
Itgav Integrin alpha V, CD51 3.35 GO:0007229 
Pde2a phosphodiesterase 2A 3.28 GO:0007165 
Stap1 Signal-transducing adaptor protein 1 3.21 GO:0007169 
Map2k4 mitogen-activated protein kinase kinase 4 3.07 GO:0007257 
Macf1 microtubule-actin crosslinking factor 1 3.07 GO:0016055 
Prex1 Phosphatidylinositol 3,4,5-dependent Rac exchanger 1 protein 2.84 GO:0035023 
Rictor Rapamycin-insensitive companion of mTOR 2.56 GO:0051896 
Gsk3a Glycogen synthase kinase-3 alpha 2.54 GO:0071879 
Col4a3bp Collagen type IV alpha-3-binding protein 2.47 GO:0007165 
Rps6ka5 Ribosomal protein S6 kinase alpha-5 2.46 GO:0007243 
Usp34 Ubiquitin carboxyl-terminal hydrolase 34 2.40 GO:0090263 
Msh6 DNA mismatch repair protein Msh6 2.35 GO:0008630 
Spn Sialophorin, CD43 antigen 2.33 GO:0007166 
Arl8a ADP-ribosylation factor-like protein 8A 2.31 GO:0007264 
Camk4 Calcium/calmodulin-dependent protein kinase type IV 2.25 GO:0007165 
Casp8 Caspase-8 2.23 GO:0097191 
Prkcd Protein kinase C delta 2.18 GO:0035556 
Mtor FKBP12-rapamycin complex-associated protein 2.16 GO:0051897 
Rbm38 RNA-binding protein 38 2.08 GO:0006977 
Atp2a2 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 1.98 GO:0006984 
Msh2 DNA mismatch repair protein Msh2 1.93 GO:0042771 
Dnaja1 DnaJ homolog subfamily A member 1 1.92 GO:0030521 
Ccdc109a Coiled-coil domain-containing protein 109A 1.86 GO:0019722 
Dgke Diacylglycerol kinase epsilon 1.80 GO:0007205 
Gng2 Guanine nucleotide-binding protein gamma-2 1.79 GO:0007165 
Tlk1 Serine/threonine-protein kinase tousled-like 1 1.77 GO:0035556 
Rab14 Ras-related protein Rab-14 1.76 GO:0007264 
Ogt UDP-N- acetylglucosaminyltransferase 1.73 GO:0048015 
Nfatc1 Nuclear factor of activated T-cells, cytoplasmic 1 1.73 GO:0035556 
Tnik Traf2 and NCK-interacting protein kinase 1.71 GO:0016055 
Slc44a2 Choline transporter-like protein 2 1.67 GO:0007165 
G3bp2 Ras GTPase-activating protein-binding protein 2 1.68 GO:0007264 
Aars Alanyl-tRNA synthetase, cytoplasmic 1.68 GO:0030968 
Smarcc1 SWI/SNF complex 155 kDa subunit 1.67 GO:0008286 
Cul3 Cullin-3 1.67 GO:0007229 
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Itpr2 Inositol 1,4,5-triphosphate receptor 2 1.66 GO:0048016 
Arf6 ADP-ribosylation factor 6 1.65 GO:0007264 
Fkbp1a FK506-binding protein 1A 1.62 GO:0007165 
Dgkz Diacylglycerol kinase zeta 1.63 GO:0007205 
Stat3 Signal transducer and activator of transcription 3 1.62 GO:0045747 
Casp2 Caspase-2  1.62 GO:0006977 
Igf2r IGF2 receptor 1.62 GO:0007186 
Nr3c1 Glucocorticoid receptor subfamily 3 group C member 1 1.62 GO:0043402 
Aip AH receptor-interacting protein 1.60 GO:0010738 
Spag9 C-jun-amino-terminal kinase-interacting protein 4 1.60 GO:0007257 
Rock1 Rho-associated protein kinase 1 1.58 GO:0007165 
Dnm1l Dynamin-1-like protein 1.58 GO:2001244 
Aak1 AP2-associated protein kinase 1 1.57 GO:0045747 
Synj1 Synaptojanin-1 1.56 GO:0048015 
Nkiras2 NF-kappa-B inhibitor-interacting Ras-like protein 2 1.56 GO:0007165 
Rab21 Ras-related protein Rab-21 1.56 GO:0007264 
Ubr2 E3 ubiquitin-protein ligase UBR2 1.53 GO:0032007 
Itgal Integrin alpha L 1.53 GO:0007229 
Itgb2 Integrin beta-2 1.53 GO:0007229 
Mapk3 Mitogen-activated protein kinase 3 1.52 GO:0032872 
Adcy7 Adenylate cyclase type 7 1.51 GO:0035556 
Gna13 Guanine nucleotide-binding protein alpha-13 1.51 GO:0007165 
Ncor1 Nuclear receptor co-repressor 1 1.50 GO:0046329 
 Signalling-related proteins down-regulated >1.5 fold   
Gene Protein F-C GO-ID 
Eef1d eukaryotic translation elongation factor 1 delta -1.50 GO:0007165 
Lrrfip2 Leucine-rich repeat flightless-interacting protein 2 -1.51 GO:0016055 
Arrb1 Beta-arrestin-1 -1.52 GO:0007165 
Txndc17 Thioredoxin domain-containing protein 17 -1.52 GO:0033209 
Cdk5 Cell division protein kinase 5 -1.57 GO:2000273 
Ikbkb Inhibitor of nuclear factor kappa-B kinase beta -1.58 GO:0023014 
Ikbkg Inhibitor of nuclear factor kappa-B kinase gamma -1.60 GO:0007250 
Ada Adenosine deaminase -1.60 GO:0060169 
Irf3 Interferon regulatory factor 3 -1.60 GO:0043123 
Wdr12 WD repeat-containing protein 12 -1.61 GO:0007219 
Igbp1 Immunoglobulin-binding protein 1 -1.61 GO:0032873 
Rps6 40S ribosomal protein S6 -1.61 GO:0031929 
Prkca Protein kinase C alpha -1.63 GO:0035556 
Arid1a AT rich interactive domain 1A -1.63 GO:0042921 
Arhgef18 Rho guanine nucleotide exchange factor 18 -1.64 GO:0035023 
Ryr2 Ryanodine receptor type 2 -1.64 GO:0030509 
Gnb2l1 Guanine nucleotide-binding protein subunit beta-2-like 1 -1.65 GO:0035556 
Sgpl1 Sphingosine-1-phosphate lyase 1 -1.67 GO:0048008 
Rgs10 Regulator of G-protein signaling 10 -1.69 GO:0009968 
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Npm1 Nucleophosmin -1.69 GO:0043516 
Pfdn5 Prefoldin subunit 5 -1.73 GO:0090090 
Ripk3 Receptor-interacting serine/threonine-protein kinase 3 -1.75 GO:0023014 
Pycard Apoptosis-associated protein containing a CARD -1.76 GO:0033209 
Pacsin2 PKC and CK substrate in neurons protein 2 -1.76 GO:0007165 
Mif Macrophage migration inhibitory factor -1.79 GO:0030330 
Stk38 Serine/threonine-protein kinase 38 -1.83 GO:0043407 
Cd247 T-cell surface glycoprotein CD3 zeta chain, CD247 -1.99 GO:0007165 
Rps6ka1 Ribosomal protein S6 kinase alpha-1 -2.10 GO:0007243 
S100a4 Protein S100-A4 -2.14 GO:0043123 
S100a13 Protein S100-A13 -2.19 GO:0043123 
Tgfbrap1 TGF beta receptor associated protein -1 -2.24 GO:0007165 
Crlf3 Cytokine receptor-like factor 3 -2.44 GO:0046427 
Rasa3 RAS p21 protein activator 3 -2.44 GO:0007165 
Cdk6 Cell division protein kinase 6 -2.48 GO:0007219 
Arl3 ADP-ribosylation factor-like protein 3 -2.59 GO:0007264 
Ifi204 7 Interferon-activable protein 204 -2.77 GO:0042771 
Ero1l ERO1-like -2.79 GO:0030968 
Plcl2 Inactive phospholipase C-like protein 2 -2.79 GO:0007165 
Gpx1 Glutathione peroxidase 1 -3.04 GO:0051897 
Stat4 Signal transducer and activator of transcription 4 -3.18 GO:0007165 
Apbb1ip Amyloid beta A4 precursor interacting protein -3.22 GO:0007165 
Rgs14 Regulator of G-protein signaling 14 -3.57 GO:0048008 
Pdap1 28 kDa heat- and acid-stable phosphoprotein -3.73 GO:0048008 
Ubash3a ubiquitin associated and SH3 domain containing, A -3.75 GO:0050860 
Anxa1 Annexin A1 -4.87 GO:0007165 
Lsp1 Lymphocyte-specific protein 1 -5.91 GO:0007165 
Rasgrp2 RAS guanyl-releasing protein 2 -8.54 GO:0035556 
Dgka Diacylglycerol kinase alpha -14.2 GO:0007205 
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 Table S3. Densitometry of western blots 
 
 
pERK 
        
 
H57 ng/ml pERK/ERK Ratio 
      Dicer lox/lox 0 2.80 
       
 
2 3.94 
       
 
10 6.43 
       
 
30 6.51 
       
 
60 7.37 
       
 
180 6.87 
       
 
360 6.56 
       CD4Cre 
Dicer lox/lox 0 1.03 
       
 
2 1.56 
       
 
10 4.80 
       
 
30 6.51 
       
 
60 7.18 
       
 
180 7.75 
       
 
360 5.36 
       
  
pERK/ERK Ratio 
      
  
1 2 3 4 
 
Mean SEM T-test 
Dicer 
lox/lox 0 min 1.213 0.389 1.213 0.389 
 
0.801 0.291 0.295 
 
15 min 11.209 10.063 12.065 13.681 
 
11.755 1.524 0.727 
 
120 min 10.758 8.908 12.490 11.377 
 
10.883 1.499 0.861 
 
480 min 11.753 12.389 10.481 10.397 
 
11.255 0.978 0.099 
  
1 2 3 4 
 
Mean SEM 
 CD4Cre 
Dicer 
lox/lox 0 min 1.155 1.002 1.150 1.002 
 
1.078 0.108 
 
 
15 min 17.996 16.383 7.800 8.803 
 
12.746 5.190 
 
 
120 min 11.419 14.347 8.125 8.440 
 
10.583 2.916 
 
 
480 min 16.720 20.381 11.363 12.838 
 
15.325 4.058 
 pAkt  
        pAkt S473/Akt 
        
 
Dicer lox/lox 1 2 3 4 
 
Mean SEM T-test 
anti-TCR 0h 1.962 
 
1 2.753 
 
1.905 0.507 0.567 
 
2h 7.339 
 
9.542 8.727 
 
8.536 0.643 0.155 
 
8h 2.939 1.971 4.176 4.912 
 
3.499 0.652 
8.2E-
05 
          anti-TCR 
+CD28 2h 7.338 
 
9.396 5.325 
 
7.353 1.175 0.126 
 
8h 0.267 1.660 3.212 6.833 
 
2.993 1.414 0.005 
 
CD4Cre 
Dicer lox/lox 1 2 3 4 
 
Mean SEM 
 anti-TCR 
+CD28 0h 0 
 
2.614 1.399 
 
1.338 0.755 
 
 
2h 12.051 
 
31.980 14.619 
 
19.550 6.259 
 
 
8h 19.839 15.624 14.260 15.771 
 
16.373 1.204 
 CD28 2h 28.014 
 
13.618 11.342 
 
17.658 5.219 
 
 
8h 34.309 28.956 12.284 22.704 
 
24.563 4.730 
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pAkt 
T308/Akt 
         
 
Dicer lox/lox 1 2 3 4 
 
Mean SEM T-test 
anti-TCR 0h 0.999 
 
1 1 
 
1 0 0.103 
 
2h 3.842 
 
2.532 2.526 
 
2.966 0.438 0.722 
 
8h 1.844 2.108 1.597 2.237 
 
1.947 0.164 0.016 
anti-TCR 
+CD28 2h 3.049 
 
2.568 2.220 
 
2.612 0.240 0.420 
 
8h 0.460 1.243 1.965 1.987 
 
1.414 0.417 0.009 
 
CD4Cre 
Dicer lox/lox 1 2 3 4 
 
Mean SEM 
 anti-TCR 0h 0.117 
 
0.964 0 
 
0.36 0.304 
 
 
2h 4.656 
 
3.206 2.040 
 
3.30 0.757 
 
 
8h 9.858 4.202 7.341 4.388 
 
6.447 1.553 
 anti-TCR 
+CD28 2h 6.268 
 
2.286 2.735 
 
3.763 1.259 
 
 
8h 6.723 4.570 2.770 5.110 
 
4.793 0.941 
  
 
